Summary Twenty patients with epithelial ovarian carcinoma were treated with high-dose cisplatin 200mg m-2 Patients were to receive three cycles at 21 day intervals. Treatment was stopped if severe myelosuppression or any neurotoxicity occurred. Overall, eight (40%) of patients responded with a complete response in five (25%). Four of 16 (25%) previously treated patients responded. The median duration of response was 44 weeks (range 6-130). In patients previously treated there was a significant association (P<0.002) between response and a remission free interval of 52 weeks or more from primary chemotherapy. Toxicity was assessable in 18 patients. Alopecia and nausea/vomiting were common. Myelosuppression was recorded in nine patients delaying planned administration in eight of 35 cycles. Five patients developed anaemia and six thrombocytopenia. Neurotoxicity affected seven patients and varying degrees of tinnitus six patients. Neurotoxicity and myelosuppression were indications for cessation of treatment in 8 patients receiving less than three cycles. Analysis revealed no significant association between toxicity and prior cisplatin exposure, age or the amount of high-dose cisplatin administered. This series reveals that it is possible to achieve good response rates using high-dose cisplatin without encountering debilitating neurotoxicity.
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Most patients with epithelial ovarian carcinoma (EOC) present with advanced disease making complete resection of tumour impossible in many cases (Katz et al., 1981) . As the tumour is relatively chemosensitive, chemotherapy is important post-operative management. Clinical response rates of over 60% have been reported with single agent cisplatin first line therapy (Lambert & Berry, 1985) . The majority of patients, however, will relapse and subsequent responses appear dependent upon the duration of primary remission (Markman et al., 1991) .
High-dose cisplatin (200 mg m2) is effective as first and second line therapy in ovarian cancer (Hainsworth et al., 1990; Ozols et al., 1985) . The rationale for dose intensification results from the steep dose-response relationship in cisplatin sensitive cell lines (Behrens et al., 1985) . The major dose limiting problem of nephrotoxicity is overcome by hypertonic saline and vigorous chloruresis (Ozols et al., 1984) (Table I) .
Previous treatment
No previously treated patient had progressed on primary therapy. The median interval from primary surgery to going on-study was 52 weeks (range 2-200).
A high-dose cisplatin regimen (200 mgm2) was administered as described by Ozols (Ozols et al., 1985) . The intention was to give a maximum of three cycles of treatment at three weekly intervals. Patients were withdrawn from the study if there was progression of disease, absence of evaluable response after two cycles or severe toxicity. Treatment was delayed if there was significant myelosuppression (WCC < 3.0; platelets < 100,000) or impared renal function (creatinine clearance < 50 ml min-). Patients were withdrawn if severe myelosuppression occurred. A careful history and clinical examination was undertaken at each visit, in particular to detect cisplatin neurotoxicity (i.e. peripheral neuropathy, ototoxicity, visual impairment and gait disturbance). Any evidence of neurotoxicity whether objective or subjective resulted in withdrawal from study. The antiemetic (UICC, 1987) . All partial and complete responses were confirmed on CT scan. Acute toxicity was evalued using WHO criteria (Miller et al., 1981 (Table II) . Of 13 patients who had prior exposure to platin containing regimens, those with CR initially but relapse within 9 months did not respond to high-dose therapy, whereas two of five with a disease free interval beyond 9 months responded. One patient with static disease following primary platin, achieved a partial response with high-dose therapy (Table III) . In previously treated patients, there was no significant association between response and the duration from primary surgery, age or the amount of prior cisplatinum exposure. A significant (P<0.002) association was noted between response and remission period of greater than 52 weeks from first line therapy.
Toxicity
Toxicity is summarized in Table IV . This was assessed in 18 patients evaluable for response. Myelosuppression occurred in nine patients four of whom developed grade 3/4 sepsis. A total of 35 cycles of treatment were administered with delay in eight (23%) due to myelosuppression. Anaemia occurred in five patients necessitating blood transfusion in four (mean of three units). Thrombocytopenia was recorded in six patients, three were given platelet transfusions (mean of 11 units), with one patient presenting with epistaxis. Nausea and vomiting were common with only two patients unaffected. Alopecia affected all but one patient in varying degrees. Neurotoxicity affected seven patients and ototoxicity six. One patient complained of hearing loss and the remainder tin- 
Discussion
The problems of nausea, vomiting and nephrotoxicity associated with high-dose cisplatin therapy have been ameliorated with antiemetics and vigourous hydration. Although myelosuppression can occur, neurotoxicity is now considered the dose limiting factor with high-dose cisplatin, which can progress even after cessation of treatment (Grunberg et al., 1989; Pollera et al., 1988 There would seem little doubt that high-dose cisplatin is effective in the treatment of ovarian cancer, but this must be balanced against its side effects. The inability to predict those who will develop neuro or ototoxicity is a continuing concern, and analysis of this series has been non contributory in this respect. There is however, clear evidence from other studies which show that neurological sequelae are dose dependent (Ozols et al., 1985 (Ozols et al., , 1984 Grunberg et al., 1989; Pollara et al., 1988) . Until the efficacy of possible neuroprotectors such as WR-2721 (Mollman et al., 1988) have been confirmed, dose intensification with cisplatin will continue to be limited by neurotoxicity. Nevertheless our series shows that dose intensification can be employed without resultant debilitating neurotoxicity, and yet achieve similar responses to that reported in other series.
